血管新素II用于分配性休克的管理:专家的共识陈述
Giovanni Landoni1,2, Andrea Cortegiani3,4, Elena Bignami5
1Anesthesia and Intensive Care Department, IRCCS San Raffaele Scientific Institute, Milan, Italy. landoni.giovanni@hsr.it.
Journal of anesthesia, analgesia and critical care
|August 16, 2024
概括
ангиотензин II (ATII) 有效地降低了对抗血管压缩剂的败血症休克所需的甲基胺. 需要进一步的试验来确认ATII在耐火分布性冲击中的疗效和安全性.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 证据支持血管素II (ATII) 对于分配性休克.
- 整合到治疗中需要评估并发症,血液动力学,成本和风险-益处.
- 由于知识的差距,临床实践需要专家的共识.
研究的目的:
- 在意大利重症监护专家之间就ATII在分布性休克中的使用发展共识.
- 解决关于ATII的应用,疗效和患者选择的临床问题.
主要方法:
- 由专家小组使用的修改后的Delphi技术.
- 在线范围研讨会定义了临床问题.
- 文献综述和临床经验信息化的陈述开发.
- 在线调查有17个陈述;共识定义为≥75%的同意 (分数7-9).
主要成果:
- 在13个声明上达成共识.
- 证实ATII在降低对抗血管压缩剂的败血症休克所需的甲基荷胺的有用性.
- 确定可能受益于ATII使用宁度的患者.
- 在降低血管酶转化酶活性的患者中,有效性已注明.
- 确定了ATII使用的潜在障碍.
结论:
- ATII是一种有价值的治疗方法,可以减少对血管压缩剂耐药性败血症休克的 катехолами因需求.
- 进一步的临床试验至关重要,以充分阐明ATII的疗效和安全性.
- 需要对ATII的作用机制和耐火分布性休克治疗优化进行研究.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
642
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
642
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
01:25Antihypertensive Drugs: Direct Renin Inhibitors
513
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
513
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
541
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
541
01:24Blood Pressure Imbalances and Circulatory Shock
763
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
763
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
145
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
145